The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Gulf War and Health: Volume 1. Depleted Uranium, Sarin, Pyridostigmine Bromide, Vaccines
significance, on the digit symbol test of psychomotor performance, EEG records of sleep, event-related potential, visual evoked potential, and computerized posturography.
These conclusions are based on retrospective studies of three different exposed populations in which the acute cholinergic signs and symptoms were documented as an acute effect of exposure. The findings from those studies are based on comparisons with control populations. One population consisted of industrial workers accidentally exposed to sarin in the United States; the other two populations were civilians exposed during terrorism episodes in Japan. The health effects listed above were documented at least 6 months after sarin exposure, and some persisted up to a maximum of 3 years, depending on the study. Whether the health effects noted above persist beyond the 3 years has not been studied.
The committee concludes that there is inadequate/insufficient evidence to determine whether an association does or does not exist between exposure to sarin at low doses insufficient to cause acute cholinergic signs and symptoms and subsequent long-term adverse health effects.
On the basis of positive findings in a study of nonhuman primates and in studies of humans exposed to organophosphate insecticides (see Appendix E), it is reasonable to hypothesize the occurrence of long-term adverse health effects from exposure to low levels of sarin. Studies of low-level exposure of workers find that organophosphate insecticides are consistently associated with higher prevalence of neurological and/or psychiatric symptom reporting (see Appendix E). However, there are no well-controlled human studies expressly of sarin’s long-term health effects at doses that do not produce acute signs and symptoms.
Anzueto A, deLemos RA, Seidenfeld J, Moore G, Hamil H, Johnson D, Jenkinson SG. 1990. Acute inhalation toxicity of soman and sarin in baboons. Fundam Appl Toxicol 14(4):676–687.
Baker DJ, Sedgwick EM. 1996. Single fibre electromyographic changes in man after organophosphate exposure. Hum Exp Toxicol 15(5):369–375.
Black RM, Harrison JM, Read RW. 1999. The interaction of sarin and soman with plasma proteins: The identification of a novel phosphonylation site. Arch Toxicol 73(2):123–126.
Brown MA, Brix KA. 1998. Review of health consequences from high-, intermediate-and low-level exposure to organophosphorous nerve agents. J Appl Toxicol 18(6): 393–408.
Bucci TJ, Parker RM. 1992. Toxicity Studies on Agents GB and GD (Phase 2): 90-Day Subchronic Study of GB (Sarin, Type II) in CD-Rats. Available from the National Technical Information Service. NTIS/AD-A248 618/1.
Bucci TJ, Parker RM, Crowell JA, Thurman JD, Gosnell PA. 1992. Toxicity Studies on Agents GB and GD (Phase 2): 90-Day Subchronic Study of GB (Sarin, Type I) in